| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MK, ARAP, NEGF2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human MDK |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MDK(Midkine)抗体的3篇参考文献，内容基于真实研究概括，但文献标题和作者为模拟示例：
---
1. **文献名称**：*Midkine as a Therapeutic Target for Cancer: Development of a Neutralizing Antibody*
**作者**：Sato, H. et al.
**摘要**：该研究开发了一种针对MDK的中和抗体，并验证其在抑制肿瘤血管生成和转移中的作用。实验表明，该抗体能显著降低多种癌症模型中MDK介导的PI3K/AKT信号通路激活，为MDK靶向治疗提供新策略。
2. **文献名称**：*Diagnostic Potential of Anti-Midkine Antibodies in Neuroblastoma*
**作者**：Chen, L. & Wang, Y.
**摘要**：研究探讨了MDK抗体在神经母细胞瘤诊断中的应用，发现患者血清中MDK水平与抗体结合能力呈负相关。通过ELISA检测，证实MDK抗体可作为生物标志物辅助早期诊断和预后评估。
3. **文献名称**：*Anti-MDK Antibody Attenuates Renal Fibrosis in Diabetic Nephropathy*
**作者**：Kim, J. et al.
**摘要**：该研究证明MDK在糖尿病肾病中通过促进纤维化和炎症加重肾损伤。使用特异性MDK抗体可显著减少胶原沉积和巨噬细胞浸润，提示其治疗慢性肾脏病的潜力。
---
如需具体文献全文，建议通过PubMed或ResearchGate以关键词“Midkine antibody”搜索近年研究。
Midkine (MDK), a heparin-binding growth factor, belongs to the pleiotrophin family and plays critical roles in cellular processes like proliferation, migration, and survival. Initially identified in embryonic tissues, MDK is minimally expressed in healthy adults but is significantly upregulated in various cancers (e.g., neuroblastoma, glioblastoma, prostate cancer) and inflammatory conditions. Its overexpression correlates with tumor progression, angiogenesis, metastasis, and poor prognosis, making it a promising biomarker and therapeutic target.
MDK antibodies are tools designed to detect or inhibit MDK activity. Research-grade antibodies facilitate studying MDK's role in disease mechanisms via techniques like immunohistochemistry and ELISA. Therapeutically, neutralizing MDK antibodies aim to block its interaction with receptors (e.g., LRP1. ALK), suppressing oncogenic signaling. Preclinical studies show such antibodies reduce tumor growth and metastasis in models of breast and lung cancers. Challenges remain in optimizing specificity and delivery, but MDK-targeted therapies, including antibody-drug conjugates, represent a growing area in precision oncology. Overall, MDK antibodies bridge diagnostic, functional, and therapeutic exploration of this multifaceted protein in human diseases.
×
